Clinical potential of emerging antiarrhythmic agents.

Analyses of randomised clinical trials have suggested that only in selective populations may antiarrhythmic drugs be effective in improving prognosis: therapy of cardiac arrhythmias, in contrast to other cardiovascular pathological conditions, has not been fully successful. The ideal treatment of arrhythmias should be guided by a sound understanding of the relative arrhythmogenic mechanisms and vulnerable parameters of the different arrhythmias. New model agents are pure class III agents, developed to fulfil these ideal characteristics and are now under active investigation (dofetilide, ibutilide, azimilide, ambasilide, E 4031, almokalant, sematilide, RP 58866 and tedisamil).
AuthorsA Capucci, D Aschieri, G Q Villani, M F Piepoli
JournalDrugs in R&D (Drugs R D) Vol. 1 Issue 4 Pg. 279-90 (Apr 1999) ISSN: 1174-5886 [Print] NEW ZEALAND
PMID10566046 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Arrhythmia Agents
  • Drugs, Investigational
  • Ion Channels
  • Animals
  • Anti-Arrhythmia Agents (pharmacology, therapeutic use)
  • Arrhythmias, Cardiac (drug therapy, physiopathology)
  • Drugs, Investigational (pharmacology, therapeutic use)
  • Humans
  • Ion Channels (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: